Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

Published : May-2020

No. of Pages : 99

order by fax Inquire before Buying request discount

1. Table of Contents
1.1. List of Tables 5
1.2. List of Figures 7
2. Deal Values in Pharmaceutical and Healthcare Industry Increased in March2020 9
2.1. Pharmaceuticals & Healthcare, Deals Summary, March 2020 9
3. Pharmaceuticals & Healthcare, Global, Deal Summary, 13
3.1. Pharmaceuticals & Healthcare, Global, Deal Analysis, March 2020 13
3.2. Pharmaceuticals & Healthcare, Global, Major Deals, March 2020 14
3.2.1. Thermo Fisher Scientific to Acquire Qiagen 15
3.2.2. Gilead Sciences Acquires Forty Seven 15
3.2.3. Silence Therapeutics Enters into Collaboration with Astrazeneca 16
3.2.4. CytomX Therapeutics Enters into Agreement with Astellas Pharma 16
3.2.5. Pfizer Raises USD1.25 Billion in Public Offering of 2.625% Notes Due 2030 17
3.3. Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, March 2020 18
3.4. Pharmaceuticals & Healthcare, Global, by Type, Deal Values, March 2020 19
4. Pharmaceuticals and Healthcare, Global, Deals, Summary, by Type 20
5. Pharmaceuticals & Healthcare, Global, Licensing Agreements, March 2020 44
6. Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 59
7. Deal Summary by Geography 77
8. Pharmaceuticals & Healthcare, Global, Top Financial Advisors 88
9. Further Information 92
9.1. Methodology 92
9.2. About GlobalData 93
9.3. Contact Us 93
9.4. Disclosure information 93
9.5. Disclaimer 93

1.1. List of Tables
Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 14
Table 2: Pharmaceuticals & Healthcare, Global, Major Deals, March 2020 14
Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), March 2020 19
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 21
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, March 2020 21
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019- March 2020 22
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 24
Table 8: Pharmaceuticals & Healthcare, Global, Top Equity Offering Deals, March 2020 24
Table 9: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 25
Table 10: Pharmaceuticals & Healthcare, Global, PE/VC, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 27
Table 11: Pharmaceuticals & Healthcare, Global, Top PE/VC Deals, March 2020 27
Table 12: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Deals Summary, October 2019- March 2020 28
Table 13: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals and Deal Values (%), March 2020 30
Table 14: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2019- March 2020 31
Table 15: Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, October 2019- March 2020 32
Table 16: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2019- March 2020 33
Table 17: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020 34
Table 18: Pharmaceuticals & Healthcare, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 35
Table 19: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront and Milestone Payments and Deal Values (US$ m), March 2020 36
Table 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 38
Table 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019- March 2020 41
Table 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Upfront and Milestone Payment and Deal values (US$ m), October 2019- March 2020 43
Table 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 45
Table 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 47
Table 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020 49
Table 26: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments (US$ m), March 2020 51
Table 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, October 2019- March 2020 54
Table 28: Pharmaceuticals & Healthcare, Global, Licensing Agreements by Therapy Area, by Upfront and Milestone Payments and Deal Values (US$ m), March 2020 56
Table 29: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Value, March 2020 56
Table 30: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Upfront Payments, March 2020 57
Table 31: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals by Total Milestone Payment, March 2020 58
Table 32: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 60
Table 33: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 63
Table 34: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 66
Table 35: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 69
Table 36: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 72
Table 37: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 74
Table 38: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 76
Table 39: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 78
Table 40: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 81
Table 41: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 83
Table 42: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 86
Table 43: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2019- March 2020 89
Table 44: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2019- March 2020 91

1.2. List of Figures
sFigure 1: Pharmaceuticals & Healthcare, Number of Deals by Therapy Area, March 2020 9
Figure 2: Pharmaceuticals & Healthcare, Number of Licensing Deals By Payment Mode, October 2019 - March 2020 10
Figure 3: Pharmaceuticals & Healthcare, Number of Deals by Region, March 2020 11
Figure 4: Pharmaceuticals & Healthcare, Number of Deals by Type, March 2020 12
Figure 5: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Values (US$ m), October 2019- March 2020 13
Figure 6: Pharmaceuticals & Healthcare, Global, Number Of Deals (%), March 2020 18
Figure 7: Pharmaceuticals & Healthcare, Global, Deal Values (%), March 2020 19
Figure 8: Pharmaceuticals & Healthcare, Global, M&As, Number of Deals and Deal Values (US$ m), October 2019- March 2020 20
Figure 9: Pharmaceuticals & Healthcare, Global, M&As by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019- March 2020 22
Figure 10: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), October 2019- March 2020 23
Figure 11: Pharmaceuticals & Healthcare, Global, Equity Offering Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020 25
Figure 12: Pharmaceuticals & Healthcare, Global, Private Equity and Venture Capital, Number of Deals and Deal Values (US$ m), October 2019- March 2020 26
Figure 13: Pharmaceuticals & Healthcare, Global, PE/VC Deals by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, October 2019- March 2020 28
Figure 14: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Number Of Deals (%), March 2020 29
Figure 15: Pharmaceuticals & Healthcare, Global, Venture Capital Deals by Stage of Financing, Deal Values (%), March 2020 30
Figure 16: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), October 2019- March 2020 31
Figure 17: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), October 2019- March 2020 33
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020 34
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 35
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 37
Figure 21: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019- March 2020 39
Figure 22: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, October 2019- March 2020 40
Figure 23: Pharmaceuticals & Healthcare, Global, Partnership Deals by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), October 2019- March 2020 42
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), October 2019- March 2020 44
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 46
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Number of Deals and Deal Values (US$ m), October 2019- March 2020 48
Figure 27: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Therapy Area, Upfront and Milestone Payments and Deal Values (US$ m), October 2019- March 2020 50
Figure 28: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Number Of Deals, October 2019- March 2020 52
Figure 29: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, Deal Values (US$ m), October 2019- March 2020 53
Figure 30: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals by Phase, by Upfront and Milestone Payments and Deal Values (US$ m), March 2020 55
Figure 31: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), October 2019- March 2020 59
Figure 32: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), October 2019- March 2020 62
Figure 33: Pharmaceuticals & Healthcare, Global, Infectious Diseases, Number of Deals and Deal Values (US$ m), October 2019- March 2020 65
Figure 34: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), October 2019- March 2020 68
Figure 35: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), October 2019- March 2020 71
Figure 36: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 73
Figure 37: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), October 2019- March 2020 75
Figure 38: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Values (US$ m), October 2019- March 2020 77
Figure 39: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Values (US$ m), October 2019- March 2020 80
Figure 40: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), October 2019- March 2020 82
Figure 41: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), October 2019- March 2020 85
Figure 42: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, Number of Deals and Deal Values (US$ m), October 2019- March 2020 88
Figure 43: Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), October 2019- March 2020 90

Filed in: Pharmaceutical

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Partnerships, Licensing, Investments and M&A Deals and Trends for March 2020 in Pharmaceuticals

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027